http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Park, Jinbong,Jeon, Yong-Deok,Kim, Hye-Lin,Lim, Hara,Jung, Yunu,Youn, Dong-Hyun,Jeong, Mi-Young,Kim, Hyun-Ju,Kim, Sung-Hoon,Kim, Su-Jin,Hong, Seung-Heon,Um, Jae-Young Hindawi Publishing Corporation 2013 Evidence-based Complementary and Alternative Medic Vol.2013 No.-
<P>Obesity has become a major health threat in developed countries. However, current medications for obesity are limited because of their adverse effects. Interest in natural products for the treatment of obesity is thus rapidly growing. Korean Medicine (KM) is characterized by the wide use of herbal formulas. However, the combination rule of herbal formulas in KM lacks experimental evidence. According to <I>Shennong's Classic of Materia Medica</I>, the earliest book of herbal medicine, <I>Veratrum nigrum</I> (VN) has antagonistic features against <I>Panax ginseng</I> (PG), and the PG-VN pair is strictly forbidden. In this study, we have shown the effects of PG, VN, and their combination on obesity in high-fat (HF) diet-induced obese mice and in 3T3-L1 cells. PG, VN, and PG-VN combination significantly reduced weight gain and the fat pad weight in HF diet-induced obese mice. They also significantly decreased lipid accumulation and the expressions of two major adipogenesis factors, PPAR<I><I>γ</I></I> and C/EBP<I><I>α</I></I>, in 3T3-L1 cells. In addition, the PG-VN combination had synergistic effects compared with the mixture of extracts of PG and VN on inhibition of PPAR<I><I>γ</I></I> and C/EBP<I><I>α</I></I> expressions at lower doses. These results indicate a new potential anti-obese pharmacotherapy and also provide scientific evidence supporting the usage of herbal combinations instead of mixtures in KM.</P>
Radicicol Inhibits iNOS Expression in Cytokine-Stimulated Pancreatic Beta Cells
Youn, Cha Kyung,Park, Seon Joo,Li, Mei Hong,Lee, Min Young,Lee, Kun Yeong,Cha, Man Jin,Kim, Ok Hyeun,You, Ho Jin,Chang, In Youp,Yoon, Sang Pil,Jeon, Young Jin The Korean Society of Pharmacology 2013 The Korean Journal of Physiology & Pharmacology Vol.17 No.4
Here, we show that radicicol, a fungal antibiotic, resulted in marked inhibition of inducible nitric oxide synthase (iNOS) transcription by the pancreatic beta cell line MIN6N8a in response to cytokine mixture (CM: TNF-${\alpha}$, IFN-${\gamma}$, and IL-$1{\beta}$). Treatment of MIN6N8a cells with radicicol inhibited CM-stimulated activation of NF-${\kappa}B$/Rel, which plays a critical role in iNOS transcription, in a dose-related manner. Nitrite production in the presence of PD98059, a specific inhibitor of the extracellular signal-regulated protein kinase-1 and 2 (ERK1/2) pathway, was dramatically diminished, suggesting that the ERK1/2 pathway is involved in CM-induced iNOS expression. In contrast, SB203580, a specific inhibitor of p38, had no effect on nitrite generation. Collectively, this series of experiments indicates that radicicol inhibits iNOS gene expression by blocking ERK1/2 signaling. Due to the critical role that NO release plays in mediating destruction of pancreatic beta cells, the inhibitory effects of radicicol on iNOS expression suggest that radicicol may represent a useful anti-diabetic activity.
Jeon, Jin Sue,Ahn, Jun Hyong,Moon, Youn-joo,Cho, Won-Sang,Son, Young-Je,Kim, Seung-Ki,Wang, Kyu-Chang,Bang, Jae Seung,Kang, Hyun-Seung,Kim, Jeong Eun,Oh, Chang Wan BMJ Publishing Group Ltd 2014 Journal of neurology, neurosurgery and psychiatry Vol.85 No.7
<P><B>Objective</B></P><P>The elevation of cellular retinoic acid-binding protein-I (CRABP-I) has been suggested as a candidate in the pathogenesis of paediatric moyamoya disease (MMD). However, few studies have addressed CRABP-I in adult onset MMD. The aim of this study was to examine the expression of CRABP-I in the cerebrospinal fluid (CSF) of adult onset MMD, and to evaluate its association with clinical presentation and postoperative haemodynamic change.</P><P><B>Methods</B></P><P>This study examined the CSF from 103 patients: bilateral MMD, n=58 (56.3%); unilateral MMD, n=19 (18.4%); atherosclerotic cerebrovascular disease (ACVD), n=21 (20.4%); and control group, n=5 (4.9%). The intensity of CRABP-I was confirmed by western blotting and expressed as the median (25th–75th percentile). The differences in CRABP-I expression according to disease entity (unilateral MMD vs bilateral MMD vs ACVD), initial presenting symptoms (haemorrhage vs ischaemia) and postoperative haemodynamic change (vascular reserve in single photon emission CT and basal collateral vessels in digital subtraction angiography) were analysed.</P><P><B>Results</B></P><P>CRABP-I intensities in bilateral MMD (1.45(0.86–2.52)) were significantly higher than in unilateral MMD (0.91(0.78–1.20)) (p=0.044) or ACVD (0.85(0.66–1.11)) (p=0.004). No significant differences were noted based on the initial presenting symptoms (p=0.687). CRABP-I was not associated with improvement in vascular reserve (p=0.327), but with decrease in basal collateral vessels (p=0.023) postoperatively.</P><P><B>Conclusions</B></P><P>Higher CRABP-I in the CSF can be associated with typical bilateral MMD pathogenesis in adults. Additionally, postoperative basal collateral change may be related to the degree of CRABP-I expression.</P>
Consideration of Regulatory Systems for Decommissioning of Nuclear Power Plants
Sang-Kyu Ahn,In-Young Jeon,Jae-Hak Cheong,Kyung-woo Choi,Chan Woo-Jeong,Youn-Keun Lee 한국방사성폐기물학회 2006 방사성폐기물학회지 Vol.4 No.4
우리나라를 포함한 일본 및 미국과 독일, 영국, 프랑스 등 유럽국가의 원자력발전소 해체에 관한 규제제도 조사를 수행하였다. 각국의 해체에 관한 규제제도에 관하여 규제정책, 법규, 인허가 절차, 검사, 대중참여 등의 항목별로 비교분석을 수행하였다. 향후 본 조사결과는 국내의 가동 원자력발전소의 폐로 및 해체에 대비한 국내 제도 개선방향 수립에 참조자료로서 활용될 예정이다. Regulatory systems for decommissioning of nuclear power plants in several countries, such as Japan, United States of America, Germany, United Kingdom, France, and Republic of Korea, are surveyed. In the survey, regulatory policies, legislations, licensing process, inspection and public involvements for decommissioning are identified and compared. Afterwards, the survey results will be utilized as a reference to establish the improvement directions of domestic regulatory system.
( Youn Hee Cho ),( Bong Min Ko ),( Shin Hee Kim ),( Yu Sik Myung ),( Jong Hyo Choi ),( Jae Pil Han ),( Su Jin Hong ),( Seong Ran Jeon ),( Hyun Gun Kim ),( Jin Oh Kim ),( Moon Sung Lee ) 대한장연구학회 2014 Intestinal Research Vol.12 No.2
Background/Aims: Colorectal cancer (CRC) develops from colonic adenomas. Type 2 diabetes mellitus (DM) is associatedwith a higher risk of CRC and metformin decreases CRC risk. However, it is not certain if metformin affects the developmentof colorectal polyps and adenomas. This study aimed to elucidate if metforminaffects the incidence of colonic polyps and adenomasin patients with type 2 DM. Methods: Of 12,186 patients with type 2 DM, 3,775 underwent colonoscopy between May2001 and March 2013. This study enrolled 3,105 of these patients, and divided them in two groups: 912 patients with metforminuse and 2,193 patients without metformin use. Patient clinical characteristics, polyp and adenoma detection rate in the twogroups were analyzed retrospectively. Results: The Colorectal polyp detection rate was lower in the metformin group than inthe non-meformin group (39.4% vs. 62.4%, P <0.01). Colorectal adenoma detection rate was significantly lower in the metformingroup than in the non-metformin group (15.2% vs. 20.5%, P <0.01). Fewer advanced adenomas were detected in the metformingroup than in the non-metformin group (12.2% vs. 22%, P <0.01). Multivariate analysis identified age, sex, Body mass index andmetformin use as factors associated with polyp incidence, whereas only metforminwas independently associated with decreasedadenoma incidence (Odd ratio=0.738, 95% CI=0.554-0.983, P =0.03). Conclusions: In patients with type 2 DM, metforminreduced the incidence of adenomas that may transform into CRC. Therefore, metformin may be useful for the preventionof CRC in patients with type 2 DM. (Intest Res 2014;12:139-145)
( Sang Youn Hwang ),( Seon-mi Lee ),( Jung Woo Im ),( Ki Jeong Jeon ),( Cheol-won Choi ),( Kyung-su Kim ),( Wan Jeon ) 대한간암학회 2019 대한간암학회지 Vol.19 No.1
Sorafenib is a well-known approved systemic therapeutic agent used in patients with advanced hepatocellular carcinoma (HCC). Regorafenib and nivolumab are approved as second-line therapeutic drugs in patients showing disease progression after sorafenib therapy. However, there is no established third- or fourth-line therapy in patients with progression after regorafenib or nivolumab treatment. Recently, the combination of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICPIs) has been attempted as a firstline treatment strategy in advanced HCC patients based on the hypothesis that combination therapy may overcome resistance in ICPI monotherapy. On the basis of this suggestion, we herein describe the case of an HCC patient demonstrating macrovascular invasion, whereby partial remission was achieved via the combination of sorafenib and nivolumab following disease progression after nivolumab therapy. Further studies on the combination of TKIs and ICPIs are necessary to determine ways to manage HCC patients showing disease progression after ICPI therapy. (J Liver Cancer 2019;19:74-78)